LIMR Chemical Genomics Center, Inc. (LCGC) founder, president and CSO Melvin Reichman, PhD has co-written a paper for Nature Reviews Drug Discovery (NRDD), entitled “Opening the lead generation toolbox,” regarding the challenges of public/private partnering and pharmaceutical collaborations in early-stage drug discovery.
The search for effective new drugs can be long, unproductive, and quite expensive. To cut costs, large pharmas have been reducing their research efforts and looking elsewhere for novel targets or strong leads. That searching has pointed to academia, where there is a push towards translational research using high throughput screening (HTS), and to other pharmas with complementary assets, including lead-generating chemical libraries. However, barriers exist to these types of collaborations. Common points of contention are issues involving confidentiality and ownership of intellectual property, knowledge pertaining to lead compounds, and how the details are handled from a business development perspective.
In the NRDD review, Dr. Reichman and his colleague Dr. Peter B. Simpson, Director of Screening Sciences at AstraZeneca, UK, discuss several current collaborative models that address the sensitive issues of knowledge sharing, intellectual property (IP) rights, and commercial pursuits. Of note is the open innovation concept Double-Blinded Drug Discovery(DBD2)®, conceived and developed by Dr. Reichman. DBD2 was designed to fully protect the IP of both parties while fostering cooperation to accelerate the process of targeted drug discovery and validation.
“Early-stage drug discovery is evolving into an endeavor in which scientific research communities in both the public and private sectors are finding new ways of achieving 'IP comfort' while sharing knowledge, expertise and resources,” explains Dr. Reichman. “Unlocking those tools across various academic and business sectors has the potential to enable the scientific community to more rapidly validate innovative targets as druggable and reinvigorate translational research.”
In addition to being the founder, president and CSO of LCGC, Dr. Reichman has recently been appointed President-Elect of the International Chemical Biology Society for the year 2014-2015. He has a PhD in Neuroscience, and has held many leadership positions including with GD Searle, Berlex Biosciences, Ligand Pharmaceuticals, and DuPont. With over 20 years in the industry, Dr. Reichman has been an invited expert on all aspects of drug discovery at more than 50 events worldwide. He has authored numerous peer-reviewed publications, has been a reviewer for many NIH study sections, and is an editor for several leading journals. A seasoned scientific advisor, Dr. Reichman lends his expertise to several start-up companies in the area of pharmaceutical research and development.
LIMR Chemical Genomics Center, Inc. (LCGC) is a biotech company that utilizes a patented automated repository and screening technology for accelerating drug discovery, including new approaches to discover synergistic combination-drugs. LCGC’s business model is a protected open-innovation framework called Double-Blinded Drug Discovery (DBD2) ® that establishes a new, public-private partnering consortium for drug-target translational research. The DBD2 model has been vetted by multiple non-profit and for-profit entities, including eighteen international academic organizations currently, with many more institutions in the process of coming on board. LCGC is a for-profit wholly owned by Lankenau Institute for Medical Research (LIMR), an independent, nonprofit biomedical research center located in suburban Philadelphia on the campus of Lankenau Medical Center, Main Line Health. Visit LCGC at lcgcinc.com.
Founded in 1985, Main Line Health (MLH) is a not-for-profit health system serving portions of Philadelphia and its western suburbs. At its core are four of the region’s respected acute care hospitals—Lankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospital—as well as one of the nation’s premier facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital; Mirmont Treatment Center for drug and alcohol recovery; and Main Line Health HomeCare & Hospice, a home health service. Main Line Health also consists of Main Line HealthCare, one of the region’s largest multi-specialty physician networks, and the Lankenau Institute for Medical Research, a non-profit biomedical research organization located on the campus of Lankenau Medical Center. Main Line Health is also comprised of four outpatient health centers located in Broomall, Collegeville, Exton and Newtown Square.
Main Line Health hospitals, with more than 10,000 employees and 2,000 physicians, are the recipients of numerous awards for quality care and service, including System Magnet® designation, the nation’s highest distinction for nursing excellence, and being named among the nation’s best employers by Forbes magazine. Main Line Health is among the area’s leaders in medicine, providing advanced patient-centered care, education and research to help our community stay healthy.
Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center, a member of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.
© 2016 Main Line Health